Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jan;6(1 Suppl 1):4-16.

Biologic Therapies for Crohn's Disease: Update from the 2009 ACG Meeting

David G Binion  1
Affiliations

Biologic Therapies for Crohn's Disease: Update from the 2009 ACG Meeting

David G Binion. Gastroenterol Hepatol (N Y). 2010 Jan.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Disclosure of Conflicts of Interest:Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

David G. Binion, MD: Dr. Binion discloses the following. Consulting fees: Abbott Laboratories, UCB, Inc.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following PIM planners and managers, Jan Hixon, RN, BSN, MA, Trace Hutchison, PharmD, Julia Kirkwood, RN, BSN, Samantha Mattiucci, PharmD and Jan Schultz, RN, MSN, CCMEP hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Figures

Figure 1
Figure 1
Patients with IBDQ response (≥16-point improvement from baseline) in the EXTEND trial of adalimumab. At week 28 and week 52, the percentages of patients achieving IBDQ responses were significantly greater for those who had mucoal healing at week 12, compared to those who had not. *P=.05.
Figure 2.
Figure 2.
Complete absence of any extraintestinal Crohn's disease manifestation (EIM), by randomized group (NRI analysis), in the CHARM trial. At weeks 26 and 56, the percent of patients experiencing resolution of EIM was significantly greater for adalimumabtreated than placebo patients.
See this image and copyright information in PMC

References

    1. Munkholm P, Langholz E, Davidsen M, et al. Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol. 1995;30:699–706. - PubMed
    1. Loftus CG, Loftus EV, Jr, Harmsen WS, et al. Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 19402000. Inflamm Bowel Dis. 2007;13:254–261. - PubMed
    1. Kappelman MD, Rifas-Shiman SL, Kleinman K, et al. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol. 2007;5:1424–1429. - PubMed
    1. Loftus EV, Jr, Schoenfeld P, Sandborn WJ. The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review. Aliment Pharmacol Ther. 2002;16:51–60. - PubMed
    1. Canavan C, Abrams KR, Hawthorne B, et al. Long-term prognosis in Crohn's disease: factors that affect quality of life. Aliment Pharmacol Ther. 2006;23:377–385. - PubMed

LinkOut - more resources